

Product Information

Cdk5

bovine, recombinant
expressed in *E. coli*
as a GST fusion protein

Product Code **C 0490**

Storage Temperature $-20\text{ }^{\circ}\text{C}$

Synonym: Cyclin Dependent Kinase-5

Product Description

Cyclin Dependent Kinase-5 (Cdk5) is a member of the serine/threonine cyclin dependent kinase family. In spite of its name, it is not regulated by cyclins nor is it a checkpoint kinase primarily involved in the regulation of cell cycle progression. Cdk5 is widely expressed in most tissues including ovary, sperm, muscle, and the central nervous system (CNS). Notwithstanding this distribution pattern, Cdk5 is predominantly active in the CNS in post-mitotic neurons when it is complexed with brain-specific activator proteins (Neuronal Cdk5 Activator, p35 and p39 isoforms, and NCK5a). The holoenzyme (active heterodimers Cdk5:p35^{NCK5a} or Cdk5:p39^{NCK5a}) is also known as Neuronal Cdc2-like Kinase (Nclk) and Brain Proline-Directed Protein Kinase (BPDK). Current understanding places Nclk as a key regulator in neurotransmission, axon guidance, CNS architecture, and pathogenesis in neurodegenerative diseases such as Alzheimer's, Amyotrophic Lateral Sclerosis, and Parkinson's Disease.¹

Unlike other Cdks, activation of Cdk5 does not require an activating kinase or autophosphorylation although it has putative phosphorylation sites. In addition, the activator proteins, p35 and p39, are structurally distinct from cyclins. p35 is known to be myristoylated. It binds to Cdk5 and recruits it to the membrane where interactions of the holoenzyme with upstream cell surface signaling receptors (such as neurotrophic factors and extracellular matrix molecules) occur. These regulator proteins are subject to proteolysis generating several truncated forms (p25 and p30) with important physiological consequences in development and pathology.² The proteasome mediated proteolysis is itself regulated by phosphorylation of the activator proteins.

Activated Cdk5 has numerous substrates.¹ Some examples are DARPP32 (Dopamine and cAMP Regulated Phosphoprotein,³ an integrator of neurotransmission), FAK (Focal Adhesion Kinase),⁴ Dynamin 1 and Amphiphysin 1 in synaptic vesicle endocytosis,⁵ voltage-dependent Ca channel, STAT3,⁶ β -catenin, NUDEL,⁷ (LIS-1 interacting protein in the growth cone), and Tau in AD brain¹ leading to neuronal apoptosis.

Activated Cdk5 clearly is uniquely important. New understanding continues to emerge on its regulation in normal CNS development and functions and its dysregulation which contributes to a number of devastating diseases.

The product is supplied in a solution of 25 mM Tris, pH 7.4, 1 mM DTT, and 30% glycerol.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

The product ships on dry ice and storage at $-20\text{ }^{\circ}\text{C}$ is recommended. It is stable for at least one year. Avoid repeated freezing and thawing. Do not store in a frost-free freezer.

Procedure

For kinase activity, Cdk5 must be reconstituted with neuronal activator proteins p25, a truncated form of p35, (p25, Product Code P 1371) or p30, a truncated form of p39, (p30, Product Code P 1246) to form the holoenzyme. One μl of Cdk5 is incubated for one hour at room temperature with 2 μl of an activator protein with 30.4 μl of reconstitution buffer.

The reconstitution buffer consists of 20 mM MOPS, pH 7.2, with 30 mM MgCl₂, 40 μM Na₃VO₄, 50 μM Na/K tartrate, 3.5 mg/ml p-nitrophenyl phosphate, 10 mM NaF, 1 mM DTT, 10 mM β-glycerophosphate, 0.15 μM microcystin, and 0.25 mg/ml BSA.

For the kinase assay, 33.4 μl of the reconstituted, activated Cdk5 solution is mixed with 16.6 μl of the kinase assay buffer (the reconstitution buffer with 0.1 mM γ-³²P-ATP [1,000 cpm/pmole] and 0.1 mM histone H1 peptide substrate). A 30 minute assay at 30 °C results in 30,000 to 70,000 cpm incorporated into the substrate.

One unit will incorporate 1 picomole of phosphate into histone H1 peptide per minute at pH 7.2 at 30 °C.

References

1. Shelton, S.B., and Johnson, G.V., Cyclin-dependent kinase-5 in neurodegeneration. *J Neurochem.*, **88(6)**, 1313-26 (2004).
2. Hisanaga, S., and Saito, T., The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. *Neurosignals*, **12(4-5)**, 221-9 (2003).
3. Scheggi, S. *et al.*, Repeated acetyl-L-carnitine administration increases phospho-Thr34 DARPP-32 levels and antagonizes cocaine-induced increase in Cdk5 and phospho-Thr75 DARPP-32 levels in rat striatum. *Eur. J. Neurosci.*, **19(6)**, 1609-20 (2004).
4. Xie, Z., and Tsai, L.H., Cdk5 phosphorylation of FAK regulates centrosome-associated microtubules and neuronal migration. *Cell Cycle*, **3(2)**, 108-10 (2004).
5. Tomizawa, K. *et al.*, Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles. *J. Cell Biol.*, **163(4)**, 813-24 (2003).
6. Fu, A.K. *et al.*, Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. *Proc. Natl. Acad. Sci. U S A.*, **101(17)**, 6728-33 (2004).
7. Niethammer, M. *et al.*, NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. *Neuron*, **28(3)**, 697-711 (2000).
8. Qi, Z. *et al.*, Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active fragment of the brain-specific activator. Kinase activation in the absence of Cdk5 phosphorylation. *J. Biol. Chem.*, **270(18)**, 10847-54 (1995).

RYMP,DG,MAM 03/05-1

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.